Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Intrahepatic cholangiocarcinoma (ICC) arises from the biliary epithelium and is a relatively rare and highly fatal neoplasm. The prognosis is poor, and survival is limited to a few months. Here, we report a case of advanced ICC that was successfully treated with apatinib, a new oral tyrosine kinase inhibitor that targets the intracellular domain of vascular endothelial growth factor receptor-2. To the best of our knowledge, this is the first case report of the successful use of apatinib for advanced ICC; this treatment has demonstrated fewer toxic effects than traditional cytotoxic chemotherapy. The progression-free survival time was 8 months. The only toxicity observed was mild hand-foot syndrome. Therefore, apatinib may be an additional option for the treatment of advanced ICC, but further prospective studies are needed to optimize the treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677377PMC
http://dx.doi.org/10.2147/OTT.S146051DOI Listing

Publication Analysis

Top Keywords

advanced icc
12
progression-free survival
8
intrahepatic cholangiocarcinoma
8
treated apatinib
8
case report
8
survival months
4
advanced
4
months advanced
4
advanced intrahepatic
4
cholangiocarcinoma patient
4

Similar Publications

Prcis: Protocol 30-2 of Melbourne Rapid Fields, online computer perimetry, provides a portable, reliable, and patient-friendly alternative to Humphrey Field Analyzer 30-2 SITA fast protocol for Japanese all severity stages of glaucoma patients.

Purpose: Melbourne Rapid Fields (MRF) online computer perimetry is a web-browser-based software that offers white-on-white threshold perimetry using any computer. This study evaluates the perimetric results of 30-2 protocol from MRF performed using a laptop computer in comparison to Humphrey Field Analyzer (HFA).

View Article and Find Full Text PDF

Malaria treatments are compromised by drug resistance, creating an urgent need to discover new drugs. We used a phenotypic high-throughput screening (HTS) platform to identify new antimalarials, uncovering three related pyrrole-, indole-, and indoline-based series with a shared α-azacyclic acetamide core. These compounds showed fast-killing activity on asexual blood-stage parasites, were not cytotoxic, and disrupted parasite intracellular pH and Na regulation similarly to cipargamin (KAE609), a clinically advanced inhibitor of the Na pump (ATP4).

View Article and Find Full Text PDF

GPT2-ICC: A data-driven approach for accurate ion channel identification using pre-trained large language models.

J Pharm Anal

August 2025

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.

Current experimental and computational methods have limitations in accurately and efficiently classifying ion channels within vast protein spaces. Here we have developed a deep learning algorithm, GPT2 Ion Channel Classifier (GPT2-ICC), which effectively distinguishing ion channels from a test set containing approximately 239 times more non-ion-channel proteins. GPT2-ICC integrates representation learning with a large language model (LLM)-based classifier, enabling highly accurate identification of potential ion channels.

View Article and Find Full Text PDF

Chronic wounds pose a growing global health challenge. Accurate assessment is essential for monitoring healing, yet traditional two-dimensional methods lack volumetric analysis. Emerging three-dimensional imaging technologies offer enhanced precision, but their clinical validation and prognostic utility remain unclear.

View Article and Find Full Text PDF

Acute myeloid leukemia: a comprehensive update.

Curr Opin Hematol

August 2025

Hematopoietic Stem Cell Transplantation Program. Hematology Department Pontificia Universidad Católica de Chile Red de Salud Christus UC.

Purpose Of Review: Acute myeloid leukemia (AML) is a biologically diverse disease that has undergone significant transformation in recent years. The rapid pace of discovery in molecular genetics, disease classification, and therapeutic development has reshaped how we approach diagnosis and treatment. This review aims to provide a timely and relevant synthesis of these advances, offering clinicians and researchers an updated perspective on AML as of 2025.

View Article and Find Full Text PDF